Pfizer (PFE)
(Delayed Data from NYSE)
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Pharma Stock Roundup: FDA Approves PFE & MRK's Oral Pills for COVID & Other Drugs
by Kinjel Shah
FDA approves Pfizer's (PFE) and Merck's (MRK) oral COVID antiviral pills and AstraZeneca's (AZN) asthma medicine, Tezspire (tezepelumab).
Pfizer ETFs to Rise on FDA's EUA for COVID-19 Oral Antiviral Pill
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the receipt of EUA for the antiviral COVID-19 pill.
Santa Arrives! High Beta & Momentum ETFs to Tap the Rally
by Sweta Killa
With the Santa Claus rally, high-beta and high-momentum ETFs are expected to outperform in the seven-day period and are intriguing choices for a short spell.
Moderna (MRNA) Down as Pfizer Paxlovid EUA May Fuel Competition
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine may face stiffer competition following the FDA's emergency approval of an oral COVID-19 pill, Pfizer's Paxlovid, which may result in lower sales.
Pfizer (PFE) Gets FDA's Emergency Use Nod for COVID Pill
by Zacks Equity Research
Pfizer's (PFE) COVID-19 pill Paxlovid is the first oral antiviral medicine, which can be prescribed as an at-home treatment for mild-to-moderate COVID-19.
Stock Market News for Dec 23, 2021
by Zacks Equity Research
Wall Street closed higher on Wednesday completing back-to-back rallies after three-days of Omicron-led decline.
Novavax (NVAX) COVID-19 Booster Jab Effective Against Omicron
by Zacks Equity Research
Novavax's (NVAX) protein-based COVID vaccine shows a cross-reactivity response against the Omicron variant. It will also start clinical studies on an Omicron-specific vaccine in first-quarter 2022.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Pfizer (PFE) Stock Moves 1.02%: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $59.55, marking a +1.02% move from the previous day.
Markets Stay Up on Omicron News; Home Sales in Focus
by Mark Vickery
Today and yesterday, we've begun to see an influx of reports about Omicron blowing through populations rapidly but rather benignly.
Novavax (NVAX) Commences COVID-19 Vaccine Booster Study
by Zacks Equity Research
Novavax (NVAX) initiates a phase III study to evaluate the booster dose of its COVID vaccine. WHO recommends administering the company's COVID vaccine booster to immunocompromised persons.
Will Lilly and Pfizer be Top Pharma Stocks Again in 2022?
by Kinjel Shah
Among the large drugmakers, stocks of Pfizer (PFE) and Eli Lilly (LLY) rose significantly in 2021 in response to their pipeline progress.
Novavax (NVAX) COVID Vaccine Gets EU Nod, 2nd Listing by WHO
by Zacks Equity Research
Novavax (NVAX) secures approval for its COVID vaccine in the European Union. Following EU approval, WHO grants second emergency use listing to the company's COVID vaccine.
Glaxo (GSK) Gets FDA Nod for HIV Preventive Injectable Drug
by Zacks Equity Research
Glaxo's (GSK) Apretude is the first and only long-acting injectable therapy approved for HIV prevention or PrEP.
Moderna (MRNA) COVID-19 Booster Jab Effective Against Omicron
by Zacks Equity Research
Data from a pseudovirus study demonstrated that the authorized booster dose of Moderna's (MRNA) COVID-19 vaccine significantly increases neutralizing antibody levels against the Omicron variant.
Biotech ETFs That Outperformed Last Week
by Sweta Killa
Biotech ETFs was the biggest gainer last week.
Pfizer (PFE) to Test 3-Dose COVID-19 Vaccine Regimen in Kids
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) to evaluate a third, 3 ug dose at least two months after the second dose of Comirnaty in children aged six months to five years for better protection against COVID-19.
Tech-Stocks Under Pressure in the Pre-Markets
by Zacks Equity Research
Tech-Stocks Under Pressure in the Pre-Markets
Markets Stay Red: Time for a Little Xmas Shopping?
by Mark Vickery
It's shaping up like a down week in the markets overall, despite a nice push higher following the most recent Fed policy adjustment mid-week.
Pfizer (PFE) COVID Pill Paxlovid Gets CHMP Support in Europe
by Zacks Equity Research
The CHMP supports the use of Pfizer's (PFE) oral COVID-19 drug, Paxlovid, to treat high-risk patients even though it has not received conditional authorization from the European Commission.
U.S. CDC Recommends mRNA COVID-19 Vaccines Over J&J's Jab
by Indrajit Bandyopadhyay
The U.S. Centers for Disease Control and Prevention prefers the use of PFE, BNTX and MRNA's mRNA-based COVID-19 vaccines instead of J&J's adenovirus-based vaccine due to higher risks of side effects.
Pharma Stock Roundup: PFE Announces Arena Buyout, LLY Ups 2021 View & More
by Kinjel Shah
Pfizer (PFE) offers to buy Arena Pharmaceuticals. Lilly (LLY) raises 2021 profit and sales outlook.
Merck's (MRK) Pneumococcal Vaccine Vaxneuvance Gets EU Nod
by Zacks Equity Research
Merck's (MRK) Vaxneuvance includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.
J&J's (JNJ) COVID-19 Booster Jab Gets CHMP Recommendation
by Zacks Equity Research
The CHMP recommends the use of the booster dose of J&J's (JNJ) COVID-19 vaccine in adults in Europe. The booster jab already enjoys authorization in the United States and from the WHO for use in adults.
Exelixis (EXEL) Initiates Study on XL092 in Advanced Solid Tumors
by Zacks Equity Research
Exelixis (EXEL) begins the dose-escalation stage of its study evaluating XL092 in combination with immuno-oncology therapies in patients with advanced solid tumors.